Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study

Abstract Background Indoleamine 2,3-dioxygenase 1 (IDO1) levels correlate with poor outcomes in urothelial carcinoma (UC). IDO1 and programmed death-ligand 1 (PD-L1) are often co-expressed. Epacadostat is a potent and highly selective inhibitor of IDO1. In a subgroup analysis of patients with advanc...

Full description

Bibliographic Details
Main Authors: Irfan Cicin, Elizabeth R. Plimack, Howard Gurney, Raya Leibowitz, Boris Y. Alekseev, Francis X. Parnis, Avivit Peer, Andrea Necchi, Joaquim Bellmunt, Hiroyuki Nishiyama, Jason Clark, Mihaela Munteanu, Ritesh Kataria, Calvin Jia, Thomas Powles, Cora N. Sternberg
Format: Article
Language:English
Published: BMC 2024-07-01
Series:BMC Cancer
Subjects:
IDO1
Epacadostat
PD-L1
Pembrolizumab
Urothelial carcinoma
Immune checkpoint inhibition
Online Access:https://doi.org/10.1186/s12885-023-11213-6

Internet

https://doi.org/10.1186/s12885-023-11213-6

Similar Items